Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Holding(s) in Company | 17 Nov 2025 |
| Director/PDMR Shareholding | 14 Nov 2025 |
| Director/PDMR Shareholding | 10 Nov 2025 |
| 9M and Q3 2025 results | 6 Nov 2025 |
| Result of General Meeting | 3 Nov 2025 |
| Total Voting Rights | 3 Nov 2025 |
| Koselugo (selumetinib) approved in the EU | 28 Oct 2025 |
| Director Declaration | 28 Oct 2025 |
| Tezspire Approved in EU for CRSwNP | 22 Oct 2025 |
| US FDA Approves Tezspire in CRSwNP | 20 Oct 2025 |
| Positive CHMP opinion for subcutaneous Saphnelo | 20 Oct 2025 |
| Agreement with US Govt to lower medicine prices | 13 Oct 2025 |